Stem Cells in Regenerative Medicine: Science, Regulation and Business Strategies

This book is a unique guide to emerging stem cell technologies and the opportunities for their commercialisation. It provides in–depth analyses of the science, business, legal, and financing fundamentals of stem cell technologies, offering a holistic assessment of this emerging and dynamic segment of the field of regenerative medicine.  Reviews the very latest advances in the technology and business of stem cells used for therapy, research, and diagnostics  Identifies key challenges to the commercialisation of stem cell technology and avenues to overcome problems in the pipeline  Written by an expert team with extensive experience in the business, basic and applied science of stem cell researchThis comprehensive volume is essential reading for researchers in cell biology, biotechnology, regenerative medicine, and tissue engineering, including scientists and professionals, looking to enter commercial biotechnology fields. INDICE: CONTRIBUTORS .FOREWORD .Bill Burns .PREFACEAlain Vertès, Nasib Qureshi, Arnold Caplan and Lee Babiss .PART I: THE STEM CELL BUSINESS .1. Therapeutic stem cells answer a strategic breakthrough need of healthcareAlain Vertès .2. Ethical considerations on the research and business of stem cellsLjiljana Minwalla .3. Projected growth of the worldwide stem cell marketEd Field .4. Cell therapy manufacturing: identifying and meeting demandJessica Carmen, David A. Brindley, Natasha L. Davie and David Smith .5. The history of stem cell transplantationHilliard M. Lazarus and Stan Gerson .6. Regulatory and intellectual property considerations for therapeutic human stem cell–based regenerative medicine product development: a U.S. perspectiveMichael Mendicino and Darin Weber .7. The regulation of stem cells in the UK and EUAlex Denoon, Julian Hitchcock and James Lawford Davies .PART II: STEM CELLS AS RESEARCH TOOLS .8. The business of stem cell research toolsErik Miljan .9. Stem cell–derived cardiomyocytes and hepatocytes as tools for drug development and screening applicationsKate Camerona, Howard Marriage, David Haya and Claire Medine .10. Stem cell tools for compound developmentTom Novak .11. Stem cell origin of cancer: prospects for functional therapeutics and regenerative medicineVinagolu K. Rajasekhar .PART III: STEM CELLS AS VETERINARY MEDICINES .12. The market of stem cell medicines for domestic and high value animalsBob J. Harmann .13. Stem cells veterinary medicines: a conceptual approachJohn Peroni and Lindsey Boone .14. Stem cells in veterinary medicines: a practical approachBob J. Harmann .15. Stem cell veterinary medicines as success signals towards human stem cell therapeuticsAlain Vertès .PART IV: STEM CELL THERAPEUTICS .16. Animal models in regenerative medicineAndrew N. Bubak, John D. Elsworth and John R. Sladek, Jr.17. Stem cell characterization: a guide to stem cell types, technologies, and future applicationsJustin Lo Re, Rezma Shrestha and Leonard Sciorra .18. Stem cell value chainsJudy Muller–Cohn, Paul Diaz and Rolf Muller .19. Stem cell culture processesRavali Raju, Shikha Sharma and Wei–Shou Hu .20. Indication transformation maps and the challenge of live cells deliveryBob Deans and Lee Babiss .21. Delivery and targeting of therapeutic cellsPaul Lin, Arnold I. Caplan and Erkki Ruoshlati .22. Hematopoietic stem cellsSteve Wolpe and Lynnet Koh .23. MSCs: the new medicinceArnold Caplan .24. Innovation and commercialization of induced pluripotent stem cellsShintaro Sengoku .25. Embryonic stem cellsRachel Eiges, Benjamin E. Reubinoff and Charles Irving .26. Allogeneic versus autologous stem cell transplantation in regenerative medicineKathy Trzaska–Accurso and Pranela Rameshwar .PART V: PERSPECTIVES .27. Clinical immunological barriers to regenerative medicine: do they matter?Cristina Trento and Francesco Dazzi .28. Challenges in the clinical development of stem cellsJohn Caulfield .29. Pricing and reimbursement of regenerative medicinesNathan Dowden .30. The role of patient advocacy in the clinical translation of regenerative medicineBernard Siegel and Alan Jakimo .31. Financing strategies for regenerative medicine start–upsCarol Julie Walton, Lee Buckler and Gregory A. Bonfiglio .32. Strategic alliances, mergers and acquisitions in regenerative medicineNafees N. Malik, Timothy E. Allsopp and Devyn M. Smith .33. History of monoclonal antibodies and lessons for the development of stem cell therapeuticsAlain Vertès and Nathan Dowden .34. Deployment of stem cell technologies in industry and healthcareAlain Vertès

• ISBN: 978-1-119-97139-9
• Editorial: Wiley–Blackwell
• Encuadernacion: Cartoné
• Páginas: 752
• Fecha Publicación: 28/08/2015
• Nº Volúmenes: 1
• Idioma: Inglés